ATE419860T1 - Kombination aus thymosin alpha1 und einem natürlichen zytokin-gemisch zur behandlung zellulärer immunschwäche - Google Patents

Kombination aus thymosin alpha1 und einem natürlichen zytokin-gemisch zur behandlung zellulärer immunschwäche

Info

Publication number: ATE419860T1
Authority: AT; Austria
Prior art keywords: cellular immune; immune deficiency; treatment; combination; natural cytokine
Prior art date: 1994-11-17

Application number

AT95940751T

Other languages

English (en)

Inventor

John W Hadden

Original Assignee

Univ South Florida

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-17

Filing date

1995-11-16

Publication date

2009-01-15

1995-11-16 Application filed by Univ South Florida filed Critical Univ South Florida

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE419860T1 publication Critical patent/ATE419860T1/de

Links

230000001413 cellular effect Effects 0.000 title abstract 3
230000007812 deficiency Effects 0.000 title abstract 3
108090000695 Cytokines Proteins 0.000 title abstract 2
102000004127 Cytokines Human genes 0.000 title abstract 2
108010078233 Thymalfasin Proteins 0.000 title 1
102400000800 Thymosin alpha-1 Human genes 0.000 title 1
239000000203 mixture Substances 0.000 title 1
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 title 1
229960004231 thymalfasin Drugs 0.000 title 1
230000002519 immonomodulatory effect Effects 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000002992 thymic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Processing Of Meat And Fish (AREA)
Medicines Containing Plant Substances (AREA)

AT95940751T 1994-11-17 1995-11-16 Kombination aus thymosin alpha1 und einem natürlichen zytokin-gemisch zur behandlung zellulärer immunschwäche ATE419860T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/341,424 US5632983A (en)	1994-11-17	1994-11-17	Method for treating secondary immunodeficiency

Publications (1)

Publication Number	Publication Date
ATE419860T1 true ATE419860T1 (de)	2009-01-15

Family

ID=23337510

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95940751T ATE419860T1 (de)	1994-11-17	1995-11-16	Kombination aus thymosin alpha1 und einem natürlichen zytokin-gemisch zur behandlung zellulärer immunschwäche

Country Status (12)

Country	Link
US (1)	US5632983A (de)
EP (2)	EP0787008B1 (de)
JP (3)	JP4416839B2 (de)
AT (1)	ATE419860T1 (de)
AU (1)	AU702770B2 (de)
CA (1)	CA2205405C (de)
DE (1)	DE69535904D1 (de)
DK (1)	DK0787008T3 (de)
ES (1)	ES2320280T3 (de)
MX (1)	MX9703627A (de)
PT (1)	PT787008E (de)
WO (1)	WO1996015800A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5674483A (en) *	1995-01-31	1997-10-07	National Jewish Medical And Research Center	Treatment for diseases involving inflammation
DE19608280A1 (de) *	1996-02-23	1997-08-28	Strathmann Ag & Co	Arzneimittel zur kausalen Therapie von HIV- oder SIV-Infektionen
US6261537B1 (en)	1996-10-28	2001-07-17	Nycomed Imaging As	Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1999020788A1 (en)	1997-10-17	1999-04-29	University Of South Florida	Method to diagnose and monitor cellular immune deficiencies
US6197751B1 (en) *	1997-11-10	2001-03-06	The United States Of America As Represented By The Department Of Health And Human Services	Thymosin α1 promotes tissue repair, angiogenesis and cell migration
IT1298487B1 (it) *	1997-12-19	2000-01-10	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
US6440448B1 (en) *	1998-03-16	2002-08-27	Joseph Intelisano	Food supplement/herbal composition for health enhancement
US6348050B1 (en) *	1999-04-30	2002-02-19	Medtronic, Inc.	Infusion systems for creating microenvironments in a living body
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
US20040247565A1 (en) *	2000-07-19	2004-12-09	Chih-Ping Liu	Method of treatment using interferon-tau
US20050226845A1 (en) *	2004-03-10	2005-10-13	Chih-Ping Liu	Method of treatment using interferon-tau
US20050118138A1 (en) *	2000-07-19	2005-06-02	Chih-Ping Liu	Method of treatment using interferon-tau
US20050201981A1 (en) *	2004-03-10	2005-09-15	Chih-Ping Liu	Method of optimizing treatment with interferon-tau
US20050118137A1 (en) *	2000-07-19	2005-06-02	Chih-Ping Liu	Method of treatment using interferon-tau
US7431920B2 (en) *	2000-07-19	2008-10-07	Pepgen Corporation	Method of treating IL-10 deficiency
US20050084478A1 (en) *	2000-10-17	2005-04-21	Chih-Ping Liu	Combination therapy using interferon-tau
AU2000275771B2 (en)	2000-09-11	2006-06-29	Therapro Technologies, Inc.	Thionin as an antineoplastic and immunostimulant
AU2002232560A1 (en) *	2000-10-27	2002-05-06	Immuno-Rx, Inc	Vaccine immunotherapy for immune suppressed patients
US20070031372A1 (en) *	2004-08-05	2007-02-08	Hadden John W	Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en)	2000-10-27	2007-02-01	Hadden John W	Vaccine immunotherapy
US20060194242A1 (en) *	2000-10-27	2006-08-31	Hadden John W	Immunotherapy for immune suppressed patients
US7182942B2 (en) *	2000-10-27	2007-02-27	Irx Therapeutics, Inc.	Vaccine immunotherapy for immune suppressed patients
US20070154399A1 (en) *	2000-10-27	2007-07-05	Hadden John W	Immunotherapy for immune suppressed patients
ATE550345T1 (de)	2001-01-10	2012-04-15	Us Health	Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
AU2002342151B2 (en) *	2001-10-26	2007-07-19	Immuno-Rx, Inc.	Immunotherapy for reversing immune suppression
UA78726C2 (en) *	2001-11-01	2007-04-25	Sciclone Pharmaceuticals Inc	Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
UA80957C2 (en) *	2001-11-01	2007-11-26	Sciclone Pharmaceuticals Inc	Method of administering a thymosin alpha 1 peptide
DK1613340T3 (da) *	2003-03-28	2010-08-30	Sciclone Pharmaceuticals Inc	Behandling af aspergillus-infektioner med thymosin alfa 1
US20100311656A1 (en) *	2003-04-23	2010-12-09	Sciclone Pharmaceuticals, Inc.	Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US6896879B2 (en) *	2003-07-03	2005-05-24	Cel-Sci Corporation	Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20060078942A1 (en) *	2004-03-10	2006-04-13	Pepgen Corporation	Method of treatment using interferon-tau
US20080025948A1 (en) *	2004-03-10	2008-01-31	Chih-Ping Liu	Methods of Treatment Using Interferon-Tau
EP1773395B1 (de) *	2004-07-30	2011-06-22	Cel-Sci Corporation	Verfahren zum verwalten von cholesterin mit einer serums- und mitogenfreien zytokin-mischung
RS52377B (sr) *	2006-05-02	2012-12-31	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Primena timozina 1, samog ili u kombinaciji sa ptx3 ili ganciklovirom, za lečenje infekcije citomegalovirusom
US8017129B2 (en)	2006-06-15	2011-09-13	SciClone Pharmaceuticals International Ltd	Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
JP5563472B2 (ja)	2007-11-28	2014-07-30	アイアールエックスセーラピューティクス，インコーポレイテッド	免疫学的効果を増大させる方法
AU2009288730B2 (en)	2008-08-25	2013-06-20	Amplimmune, Inc.	Compositions of PD-1 antagonists and methods of use
JP2012500855A (ja) *	2008-08-25	2012-01-12	アンプリミューン、インコーポレーテッド	Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8066949B2 (en) *	2008-09-26	2011-11-29	Exxonmobil Research & Engineering Company	Scrubber for fluid coker unit
WO2010129947A2 (en) *	2009-05-08	2010-11-11	Sciclone Pharmaceuticals, Inc.	Alpha thymosin peptides as vaccine enhancers
CA3017298C (en) *	2009-05-15	2021-09-28	Irx Therapeutics, Inc.	Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
US20110070269A1 (en) *	2009-09-24	2011-03-24	Therapro Technologies, Inc.	Lipopolysaccharide isolated from pyrularia tissue and/or pyrularia-associated bacteria and uses thereof
ES2667476T3 (es)	2009-12-08	2018-05-11	Irx Therapeutics, Inc.	Método para invertir la supresión inmunitaria de células de Langerhans
CN110101843A (zh) *	2018-02-01	2019-08-09	北京科诺科服生物科技有限公司	一种抗肿瘤蛋白质及其应用
WO2023072863A1 (en) *	2021-10-25	2023-05-04	Ellennbe Gmbh	Pharmaceutical composition and kit comprising an immunomodulatory substance for treating diseases
WO2024084038A1 (en) *	2022-10-20	2024-04-25	Ellennbe Gmbh	Platform technology for treatment of inflammatory, immunological and/or autoimmunological diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4079127A (en)	1976-10-28	1978-03-14	Board Of Regents Of The University Of Texas	Thymosin alpha 1
US4116951A (en) *	1977-04-22	1978-09-26	Hoffmann-La Roche Inc.	[Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en)	1978-01-23	1979-04-10	Hoffmann-La Roche Inc.	Synthesis of thymosin α1
DE2919592A1 (de) *	1979-05-15	1981-01-15	Max Planck Gesellschaft	Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4470926A (en) *	1980-01-18	1984-09-11	Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V.	Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1
DE3100974A1 (de) *	1980-01-18	1982-01-21	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen	Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
US4612365A (en) *	1980-03-25	1986-09-16	Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften	Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4293455A (en)	1980-04-07	1981-10-06	Rockefeller University	N.sup.α -Desacetylthymosinα1 and process
US4390623A (en)	1980-10-02	1983-06-28	Hooper Trading Company	Serum-free and mitogen-free T-cell growth factor and process for making same
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4448879A (en)	1981-03-26	1984-05-15	Hooper Trading Company	High yield process for in vitro production of serum-free and mitogen-free interleukin-2
US4447233A (en)	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
US4504415A (en)	1983-04-04	1985-03-12	Hoffman-La Roche Inc.	Synthesis of thymosin α1 and desacetyl thymosin α1
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
FR2546267B1 (fr)	1983-05-19	1985-07-26	Aubry Cie Sa	Structure d'enveloppe ou de panneau composite multicouches
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
US4614731A (en)	1983-09-15	1986-09-30	Hoffmann-La Roche Inc.	Peptide having immunopotentiating activity similar to thymosin alpha1
US4659694A (en) *	1983-10-27	1987-04-21	Hoffmann-La Roche Inc.	Prothymosin alpha
US4569790A (en)	1984-03-28	1986-02-11	Cetus Corporation	Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4716148A (en) *	1984-08-13	1987-12-29	Hoffman-La Roche Inc.	Prothymosin alpha
US5093114A (en) *	1985-03-16	1992-03-03	Burroughs Wellcome Co.	Treatment of human viral infections
US4935233A (en) *	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
IT1238231B (it) *	1989-12-18	1993-07-12	Consiglio Nazionale Ricerche	Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
CN1094310A (zh) *	1992-12-15	1994-11-02	托马斯·C·梅里根	人体免疫缺陷性病毒感染用组合式化学疗法

1994
- 1994-11-17 US US08/341,424 patent/US5632983A/en not_active Expired - Lifetime
1995
- 1995-11-16 PT PT95940751T patent/PT787008E/pt unknown
- 1995-11-16 EP EP95940751A patent/EP0787008B1/de not_active Expired - Lifetime
- 1995-11-16 WO PCT/US1995/015038 patent/WO1996015800A1/en not_active Ceased
- 1995-11-16 AU AU42400/96A patent/AU702770B2/en not_active Ceased
- 1995-11-16 DK DK95940751T patent/DK0787008T3/da active
- 1995-11-16 DE DE69535904T patent/DE69535904D1/de not_active Expired - Lifetime
- 1995-11-16 ES ES95940751T patent/ES2320280T3/es not_active Expired - Lifetime
- 1995-11-16 EP EP09150028A patent/EP2036569A3/de not_active Withdrawn
- 1995-11-16 AT AT95940751T patent/ATE419860T1/de active
- 1995-11-16 CA CA002205405A patent/CA2205405C/en not_active Expired - Fee Related
- 1995-11-16 JP JP51700796A patent/JP4416839B2/ja not_active Expired - Fee Related
1997
- 1997-05-16 MX MX9703627A patent/MX9703627A/es not_active IP Right Cessation
2006
- 2006-08-21 JP JP2006224746A patent/JP2006306898A/ja not_active Withdrawn
2008
- 2008-09-25 JP JP2008246964A patent/JP2009029830A/ja active Pending

Also Published As

Publication number	Publication date
CA2205405C (en)	2003-02-04
WO1996015800A1 (en)	1996-05-30
JP4416839B2 (ja)	2010-02-17
DE69535904D1 (de)	2009-02-26
MX9703627A (es)	1998-07-31
DK0787008T3 (da)	2009-05-11
EP2036569A3 (de)	2009-04-01
AU702770B2 (en)	1999-03-04
CA2205405A1 (en)	1996-05-30
JPH10509955A (ja)	1998-09-29
ES2320280T3 (es)	2009-05-20
EP0787008B1 (de)	2009-01-07
EP2036569A2 (de)	2009-03-18
JP2006306898A (ja)	2006-11-09
US5632983A (en)	1997-05-27
JP2009029830A (ja)	2009-02-12
AU4240096A (en)	1996-06-17
EP0787008A1 (de)	1997-08-06
EP0787008A4 (de)	1999-02-10
PT787008E (pt)	2009-03-23

Legal Events

Date

Code

Title

Description

2009-09-15

UEP

Publication of translation of european patent specification

Ref document number: 0787008

Country of ref document: EP

Publication	Publication Date	Title
ATE419860T1 (de)	2009-01-15	Kombination aus thymosin alpha1 und einem natürlichen zytokin-gemisch zur behandlung zellulärer immunschwäche
DK0585943T3 (da)	1998-09-23	Opløselige ligander for CD40
NZ227787A (en)	1991-10-25	Peptides and compositions having growth hormone regulatory effects
DK53497A (da)	1997-05-09	Osteoinduktive præparater
DE69027865D1 (de)	1996-08-22	ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
FI970747A0 (fi)	1997-02-21	Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
DE69003977D1 (de)	1993-11-25	Verfahren und Einrichtung zur Bestimmung des Stengelgehaltes von Tabak.
ATA152786A (de)	1993-06-15	Verfahren und turbo-sichter zum streuwindsichten, insbesondere von zement
FI971420A0 (fi)	1997-04-04	Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
ATE182793T1 (de)	1999-08-15	Zusammensetzung und verfahren zur verhinderung und behandlung von entzündung mit immunoglobin a
ATE30326T1 (de)	1987-11-15	Cyclische pentapeptide mit somatostatin antagonistischer wirksamkeit und verfahren zur behandlung von saeugetieren damit.
DE69227837D1 (de)	1999-01-21	Verfahren und vorrichtung zur bestimmung der konzentration von bestandteilen in atmungsluft
DE68917433D1 (de)	1994-09-15	Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
ATE143804T1 (de)	1996-10-15	Zusammensetzung zur behandlung von mastitis und metritis
DE69213529D1 (de)	1996-10-17	Nylonzusammensetzung mit erhöhter Hydrolysierbarkeit und Verfahren zur Erhöhung der Hydrolysierbarkeit von Nylon
EP0285441A3 (en)	1990-05-30	Synergistic immunostimulating composition and method
PL325667A1 (en)	1998-10-12	Antibodies effective against fas
GR870518B (en)	1987-08-03	Herbicide compositions based on biscarbamate and method of herbicide treatment using said compositions
ID19618A (id)	1998-07-23	Komposisi komposisi asam amino dan pemakaiannya dalam makanan untuk pengobatan
MX9100179A (es)	1992-08-10	Composicion y metodo para el tratamiento de disfunciones neurologicas en mamiferos
ATE167628T1 (de)	1998-07-15	Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
DE3674585D1 (de)	1990-10-31	Zubereitung zur behandlung und vorbeugung von diarrhoee bei menschen und tieren und verfahren zu deren herstellung.
EP0158880A3 (en)	1986-01-08	Liposomes with inhalable allergens for treatment of allergies, method for their preparation and pharmaceutical compositions containing them
EP0540575A4 (en)	1994-06-08	Human meg-csf protein and methods
EP0539516A4 (de)	1994-02-23